Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mass Spectrometry is key technology for studying critical molecules and pathways. Defining molecular targets is crucial for the process of drug development. In our group, we are focused on using proteomics, mass spectrometry and biochemical approaches to understand disease processes.

Kessler lab group picture during lab away day in London 2018 at Sky Gardens.

The Kessler group has expertise in proteomics based methodologies and hosts a platform containing a variety of chromatography equipment and mass spectrometers. We apply mass spectrometry to discover "molecular windows" of human diseases to accelerate target discovery.

The group consists of three teams:

- Ubiquitin Protease Biology Team

- Discovery Proteomics Facility Team

- Metabolomics Team

Kessler Lab TDI    Discovery Proteomics Facility

Our team